Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.316 -0.054 (-3.94%)
Streaming Delayed Price Updated: 10:20 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗
Lexicon Pharmaceuticals (LXRX) Q3 2025 earnings crush estimates with a massive revenue beat, driven by its Novo Nordisk partnership. The stock rose on the strong results and promising pipeline... 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Lexicon Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1... 
Via Benzinga
Topics Stocks
News headline image
Lexicon (LXRX) Q2 Revenue Soars 1,706% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5% ↗
Lexicon Pharmaceuticals (LXRX) reports strong Q2 2025 earnings with $28.9M revenue, beating estimates by 482%. Stock rises 9.5% on profit surprise and pipeline progress. 
Via Chartmill
News headline image
A Preview Of Lexicon Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Top 2 Health Care Stocks That May Crash This Month ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Curious about the most active stocks on Monday? ↗
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. 
Via Chartmill
News headline image
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst ↗
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
News headline image
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60% ↗
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Friday's session: most active stocks ↗
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action! 
Via Chartmill
News headline image
Top movers in Friday's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Top movers in Friday's pre-market session ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 ↗
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
News headline image
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected ↗
 
Via Benzinga
Topics Economy
News headline image
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk ↗
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Monday's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.